Mind Medicine MindMed Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $52,124 | $36,169 |
| General and administrative | 41,742 | 30,162 |
| Total operating expenses | 93,866 | 66,331 |
| Loss from operations | (93,866) | (66,331) |
| Other income/(expense): | ||
| Interest income, net | 4,664 | 1,495 |
| Foreign exchange gain, net | 157 | 195 |
| Change in fair value of 2022 USD Financing Warrants | (6,636) | 7,843 |
| Other (expense)/income | (51) | 2 |
| Total other (expense)/income, net | (1,866) | 9,535 |
| Net loss | (95,732) | (56,796) |
| Other comprehensive loss: | ||
| Loss on foreign currency translation | (284) | (419) |
| Comprehensive loss | $(96,016) | $(57,215) |
| Net loss per common share, basic and diluted | $(2.44) | $(1.84) |
| Weighted-average common shares, basic and diluted (Note 2) | 39,157,420 | 30,857,463 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.